ANA Webinar: MS DMTs during COVID-19

During this 60-minute session, Dr. John Ciotti hosted Drs. Elena Grebenciucova, Scott Newsome, and Brandon Moss discussing implications of disease-modifying therapies for MS on COVID-19 susceptibility/severity, starting/switching therapies, vaccine responses, and other clinical considerations.

Target Audience

Neurologists and neurological researchers 

Activity summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
    The American Neurological Association is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The American Neurological Association designates this Enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 Participation
Activity opens: 
08/24/2020
Activity expires: 
08/23/2023
Rating: 
0

The American Neurological Association is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Neurological Association designates each enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
    The American Neurological Association is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The American Neurological Association designates this Enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 Participation
Please login or register to take this activity.